In a breakthrough for Alzheimer’s disease research, Anavex Life Sciences has announced promising results from their phase 2b/3 clinical trial of
blarcamesine (ANAVEX®2-73). This investigational drug has shown significant
efficacy in reducing amyloid-ß biomarkers and slowing brain atrophy in patients
with early-stage Alzheimer’s.
According to Anavex Life Sciences, the study, which involved 508 participants across five countries,
highlighted the potential of blarcamesine to slow cognitive decline. Patients
treated with the drug exhibited notable improvements in both cognitive and
functional assessments compared to those who received a placebo. Specifically,
the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) and Clinical
Dementia Rating Scale Sum of Boxes revealed significant differences favoring blarcamesine.
Dr. Marwan Noel Sabbagh, a leading neurologist and chairman of the Scientific Advisory Board,
emphasized the significance of the findings. “There is hope that new
therapies for Alzheimer’s, such as blarcamesine, may slow the progression of
this devastating disease,” he stated. The drug’s oral administration and
favorable safety profile make it a promising candidate for widespread use.
Anavex Life Sciences also reported that the most common adverse event was mild to moderate
dizziness, which was transient and manageable. This side effect was more
frequently observed during the titration phase but lessened during maintenance.
Christopher U Missling, PhD, CEO of Anavex, expressed gratitude to all involved in the study. “Our
clinical development is a testament to our determination to follow the
science,” he remarked, underscoring the company’s commitment to advancing
Alzheimer’s treatment.
As Anavex Life Sciences continues to analyze the full data set, the medical community remains
hopeful. The advancements in biomarker reduction and cognitive slowing could
mark a significant step forward in Alzheimer’s research, potentially offering
new avenues for treatment. See related link for additional information.
Like their page on Facebook.com